Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
RESEARCH TOOLSreports
Viridian Therapeutics (VRDN) Stock Price & Analysis
981 Followers
VRDN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.93 - $30.30
Previous Close$17.51
Volume1.01M
Average Volume (3M)982.60K
Market Cap
$1.10B
Enterprise Value$917.65M
Total Cash (Recent Filing)$201.41M
Total Debt (Recent Filing)$20.00M
Price to Earnings (P/E)-3.3
Beta0.68
Next Earnings
May 08, 2024EPS Estimate
-$1.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.32
Shares Outstanding62,767,570
10 Day Avg. Volume1,311,566
30 Day Avg. Volume982,599
Standard Deviation0.42
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)3.02
Price to Sales (P/S)620.24
Price to Cash Flow (P/CF)-7.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.69K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.39
Forecast
1Y Price Target
$36.82Price Target Upside110.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Viridian Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VRDN FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest stock price was $10.93 and its highest was $30.30 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Currently, no data Available
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s upcoming earnings report date is May 08, 2024 which is in 19 days.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on Mar 13, 2024. The company reported -$1.35 earnings per share for the quarter, missing the consensus estimate of -$0.978 by -$0.372.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate is -$1.09.
How many shares outstanding does Viridian Therapeutics have?
Viridian Therapeutics has 62,767,570 shares outstanding.
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -$1.35 in its last earnings report, missing expectations of -$0.978. Following the earnings report the stock price went up 1.193%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Among the largest hedge funds holding Viridian Therapeutics’s share is Maverick Capital ltd. It holds Viridian Therapeutics’s shares valued at 51M.
---
Viridian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.82 (110.28% Upside)
$36.82 (110.28% Upside)
Blogger Sentiment
Bullish
VRDN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.3%
Last 30 Days ▲ 10.6%
Last 30 Days ▲ 10.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.07%
12-Months-Change
Fundamentals
Return on Equity
-56.80%
Trailing 12-Months
Asset Growth
12.72%
Trailing 12-Months
Company Description
Viridian Therapeutics
Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
---
VRDN Earnings Call
Q1 2023
0:00 / 0:00
---
VRDN Stock 12 Months Forecast
Average Price Target
$36.82
▲(110.28% Upside)
Technical Analysis
Best Analysts Covering VRDN
1 Year
1 Year Success Rate
13/28 ratings generated profit
1 Year Average Return
-0.92%
reiterated a buy rating last month
Copying Laura Chico's trades and holding each position for 1 Year would result in 46.43% of your transactions generating a profit, with an average return of -0.92% per trade.
---